For people with aneurysmal subarachnoid hemorrhage and anemia, there was no significant neurological benefit from getting red ...
Blood is one of the oldest drugs in the world, but after many decades of research, it is still not always clear when a blood ...
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
Beam Therapeutics (BEAM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
SAN DIEGO -- Treatment with hydroxyurea led to more hematologic dose-limiting toxicities (DLTs) compared with placebo in ...
Complete SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
Thalassemia is a condition in which the body makes less hemoglobin, a protein that's an important part of red blood cells. This results in red blood cells being destroyed, which is known as hemolytic ...
Neonatal anemia can have lasting impacts on the growth and development of children. Anemia is highly prevalent among pregnant ...